New pill could stop scalp scarring and hair loss

NCT ID NCT07532603

Recruiting now Disease control Sponsor: Priovant Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an oral medication called brepocitinib for adults with lichen planopilaris, a condition that causes scalp inflammation, scarring, and hair loss. About 342 participants will receive either the drug or a placebo to see if it reduces symptoms and improves scalp appearance. The goal is to find a treatment that controls the disease, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LICHEN PLANOPILARIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lichen planopilaris lichen planus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LICHEN PLANOPILARIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinical Trial Site
RECRUITING

Phoenix, Arizona, 85006, United States
Clinical Trial Site
RECRUITING

Portland, Oregon, 97210, United States
Clinical Trial Site
RECRUITING

Smyrna, Tennessee, 37167, United States
Clinical Trial Site
RECRUITING

Austin, Texas, 78613, United States
Clinical Trial Site
RECRUITING

Cedar Park, Texas, 78613, United States